

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
10 November 2022 (10.11.2022)



(10) International Publication Number  
**WO 2022/236142 A2**

- (51) **International Patent Classification:**  
Not classified
- (21) **International Application Number:**  
PCT/US2022/028202
- (22) **International Filing Date:**  
06 May 2022 (06.05.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
63/185,896 07 May 2021 (07.05.2021) US  
63/283,147 24 November 2021 (24.11.2021) US
- (71) **Applicant: SENTI BIOSCIENCES, INC.** [US/US]; 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US).
- (72) **Inventors: GONZALEZ-JUNCA, Alba;** c/o Senti Biosciences, INC., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US). **ROGUEV, Assen Boyanov;** c/o Senti Biosciences, INC., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US). **FRANKEL, Nicholas;** c/o Senti Biosciences, INC., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US).
- (74) **Agent: NEWMAN, Zachary R.** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7TH FL, Boston, Massachusetts 02210 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) **Title:** CHIMERIC RECEPTORS AND METHODS OF USE THEREOF

**Antibody-1(Light) – CDR annotation with Chothia scheme**

| LFR1   |    |    |    |    |        |    |    |    |    |    |      |     |     |     |      |     |     |     |    |    |    |
|--------|----|----|----|----|--------|----|----|----|----|----|------|-----|-----|-----|------|-----|-----|-----|----|----|----|
| 1      | 2  | 3  | 4  | 5  | 6      | 7  | 8  | 9  | 10 | 11 | 12   | 13  | 14  | 15  | 16   | 17  | 18  | 19  | 20 | 21 | 22 |
| D      | I  | Q  | M  | T  | Q      | S  | P  | A  | S  | L  | S    | A   | S   | V   | G    | E   | T   | V   | T  | M  | T  |
| CDR-L1 |    |    |    |    |        |    |    |    |    |    | LFR2 |     |     |     |      |     |     |     |    |    |    |
| 23     | 24 | 25 | 26 | 27 | 28     | 29 | 30 | 31 | 32 | 33 | 34   | 35  | 36  | 37  | 38   | 39  | 40  | 41  | 42 | 43 | 44 |
| C      | R  | A  | S  | E  | N      | I  | Y  | S  | Y  | L  | A    | W   | Y   | Q   | Q    | K   | Q   | G   | K  | S  | P  |
| LFR2   |    |    |    |    | CDR-L2 |    |    |    |    |    |      |     |     |     | LFR3 |     |     |     |    |    |    |
| 45     | 46 | 47 | 48 | 49 | 50     | 51 | 52 | 53 | 54 | 55 | 56   | 57  | 58  | 59  | 60   | 61  | 62  | 63  | 64 | 65 | 66 |
| Q      | L  | L  | V  | F  | N      | A  | E  | T  | L  | P  | E    | G   | V   | P   | S    | R   | F   | S   | G  | T  | G  |
| LFR3   |    |    |    |    |        |    |    |    |    |    |      |     |     |     |      |     |     |     |    |    |    |
| 67     | 68 | 69 | 70 | 71 | 72     | 73 | 74 | 75 | 76 | 77 | 78   | 79  | 80  | 81  | 82   | 83  | 84  | 85  | 86 | 87 | 88 |
| S      | G  | T  | H  | F  | S      | L  | R  | I  | N  | S  | L    | Q   | P   | E   | D    | F   | G   | S   | Y  | Y  | C  |
| CDR-L3 |    |    |    |    |        |    |    |    |    |    | LFR4 |     |     |     |      |     |     |     |    |    |    |
| 89     | 90 | 91 | 92 | 93 | 94     | 95 | 96 | 97 | 98 | 99 | 100  | 101 | 102 | 103 | 104  | 105 | 106 | 107 |    |    |    |
| Q      | H  | H  | Y  | V  | I      | P  | W  | T  | F  | G  | G    | G   | T   | K   | L    | E   | I   | K   |    |    |    |

FIG. 1

(57) **Abstract:** Provided herein are chimeric proteins comprising an antigen-binding domain specific for V-Set And Immunoglobulin Domain Containing 2 (VSIG2). Also provided herein are cells, polynucleotides, vectors, compositions, and methods directed to chimeric proteins comprising an antigen-binding domain specific for VSIG2.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*